Hidroferol Choque (Calcifediol)

Hidroferol Choque is an oral vitamin D supplement that contains the active ingredient calcifediol, a 25‑hydroxyvitamin D3 analogue. It is marketed in the European Union as an over‑the‑counter product and is intended for use in adults with low vitamin D levels or related calcium metabolism concerns. The formulation provides a source of 25‑hydroxyvitamin D that can be further converted to the hormonally active form to support bone health.

Hidroferol Choque is used to address conditions related to insufficient vitamin D status and calcium balance.

- Treatment of documented vitamin D deficiency. - Prevention of hypocalcemia in individuals with low calcium intake. - Support of bone mineralization in adults at risk of osteopenia or osteoporosis. - Adjunct therapy for chronic kidney disease patients with impaired conversion to active vitamin D. - Maintenance of normal serum calcium and phosphate levels in persons with limited sun exposure.

Adverse reactions reported with calcifediol-containing products are generally mild, but rare serious events may occur.

Common: - Mild gastrointestinal discomfort such as nausea, abdominal cramping, or loose stools, typically resolving without intervention. - Transient headache or light‑headed feeling that usually subsides within a few hours. - Slight, asymptomatic rise in serum calcium levels detected on routine laboratory testing. - General fatigue or mild drowsiness, especially after the first dose.

Serious: - Hypercalcemia characterized by nausea, vomiting, excessive thirst, polyuria, and possible cardiac rhythm disturbances, requiring medical evaluation. - Hypercalciuria that may promote kidney stone formation or renal colic, necessitating monitoring. - Allergic skin reactions including rash, pruritus, or urticaria, which may progress if exposure continues. - Rare anaphylactic reaction presenting with airway swelling, hypotension, and systemic symptoms, demanding immediate emergency care.

When considering Hidroferol Choque, certain safety considerations should be reviewed to minimize risk.

- Avoid use in individuals with known hypercalcemia or hypervitaminosis D. - Caution in patients with renal impairment; monitor calcium and phosphate levels. - Not recommended for infants, children, or pregnant women without medical supervision. - Assess baseline serum calcium, phosphate, and vitamin D status before initiating therapy. - Concomitant use with thiazide diuretics may increase calcium levels; monitor accordingly. - Adjust dose or discontinue if persistent elevated calcium is observed.

Calcifediol may affect the pharmacokinetics or pharmacodynamics of several other agents.

Avoid: - High‑dose vitamin D analogues or calcitriol, which can cause additive hypercalcemia. - Thiazide or loop diuretics that alter calcium excretion. - Orlistat, which may reduce absorption of fat‑soluble vitamins.

Use with caution: - Calcium supplements, as combined use may raise serum calcium. - Anticonvulsants (e.g., phenobarbital, phenytoin) that increase vitamin D metabolism, potentially reducing efficacy. - Glucocorticoids that accelerate vitamin D catabolism, possibly requiring dose adjustment. - Bisphosphonates, where altered calcium balance may affect bone turnover monitoring.